RCCP
MCID: RNL065
MIFTS: 71

Renal Cell Carcinoma, Papillary, 1 (RCCP)

Categories: Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Renal Cell Carcinoma, Papillary, 1

MalaCards integrated aliases for Renal Cell Carcinoma, Papillary, 1:

Name: Renal Cell Carcinoma, Papillary, 1 57 29 13 6
Papillary Renal Cell Carcinoma 38 12 53 59 29 15 73
Papillary Renal Cell Carcinoma, Sporadic 6 44 73
Papillary Renal Cell Adenocarcinoma 53 59
Renal Cell Carcinoma, Papillary 57 13
Rccp 53 75
Renal Cell Carcinoma, Papillary, 1, Familial and Somatic 57
Papillary Renal Cell Carcinoma, Bilateral - 53
Papillary Renal Cell Carcinoma, Familial - 53
Papillary Renal Cell Carcinoma, Multiple - 53
Papillary Renal Cell Carcinoma, Sporadic - 53
Hereditary Papillary Renal Cell Carcinoma 59
Sporadic Papillary Renal Cell Carcinoma 12
Papillary Renal Carcinoma, Malignant - 53
Type 1 Papillary Renal Cell Carcinoma 73
Hereditary Papillary Renal Carcinoma 73
Chromophilic Renal Cell Carcinoma 75
Chromophil Carcinoma of Kidney 12
Renal Cell Carcinoma Papillary 75
Papillary Kidney Carcinoma 12
Renal Cell Carcinoma 73
Renal Adenocarcinoma 53
Rccp1 57
Hprcc 59
Prcc 75

Characteristics:

Orphanet epidemiological data:

59
hereditary papillary renal cell carcinoma
Inheritance: Autosomal dominant; Age of onset: Adult;

HPO:

32
renal cell carcinoma, papillary, 1:
Onset and clinical course incomplete penetrance
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 59  
Rare renal diseases


External Ids:

OMIM 57 605074
Disease Ontology 12 DOID:4465
NCIt 50 C27890 C6975
SNOMED-CT 68 4797003
UMLS via Orphanet 74 C1306837 C0879257 C2931899
ICD10 via Orphanet 34 C64
MESH via Orphanet 45 C538614
SNOMED-CT via HPO 69 263681008

Summaries for Renal Cell Carcinoma, Papillary, 1

OMIM : 57 Hereditary papillary renal cell carcinoma is characterized by the development of multiple, bilateral papillary renal tumors (Zbar et al., 1995). The transmission pattern is consistent with autosomal dominant inheritance with incomplete penetrance. Papillary renal cell carcinoma is histologically and genetically distinct from 2 other forms of inherited renal carcinoma, von Hippel Lindau disease (193300), caused by mutation in the VHL gene (608537) on chromosome 3, and a form associated with the chromosome translocation t(3;8), as described by Cohen et al. (1979). Bodmer et al. (2002) reviewed the molecular genetics of familial and nonfamilial cases of renal cell carcinoma, including the roles of VHL, MET, and translocations involving chromosomes 1, 3, and X. For background information and a discussion of genetic heterogeneity of nonpapillary renal cell carcinoma, see RCC (144700). See also a hereditary syndrome of predisposition to uterine leiomyomas and papillary renal cell carcinoma (HLRCC; 150800) caused by germline mutation in the FH gene (136850). (605074)

MalaCards based summary : Renal Cell Carcinoma, Papillary, 1, also known as papillary renal cell carcinoma, is related to metanephric adenoma and childhood kidney cell carcinoma, and has symptoms including flank pain An important gene associated with Renal Cell Carcinoma, Papillary, 1 is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Afinitor and Avastin have been mentioned in the context of this disorder. Affiliated tissues include kidney, thyroid and bone, and related phenotypes are papillary renal cell carcinoma and Decreased viability

Disease Ontology : 12 A renal cell carcinoma that is characterized by the development of multiple, bilateral papillary renal tumors.

NIH Rare Diseases : 53 Papillary renal cell carcinoma (PRCC) is a type of cancer that occurs in the kidneys. It accounts for about 10-15% of all renal cell carcinomas.Renal cell carcinomas are a type of kidney cancer that develop in the lining of very small tubes (tubules) in the kidney.The term "papillary" describes the finger-like projections that can be found in most of the tumors. PRCC can be divided into two types: type 1, which is more common and usually grows more slowly and type 2, which are usually more aggressive .Though the exact cause of papillary renal cell carcinoma is unknown, smoking, obesity, and genetic predisposition conditions (such as hereditary leiomyomatosis and renal cell cancer) may contribute to the development of this type of cancer. Treatment often begins with surgery to remove as much of the cancer as possible, and may be followed by radiation therapy, chemotherapy, biological therapy, or targeted therapy.

UniProtKB/Swiss-Prot : 75 Renal cell carcinoma papillary: A subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium.

Related Diseases for Renal Cell Carcinoma, Papillary, 1

Diseases related to Renal Cell Carcinoma, Papillary, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 230)
# Related Disease Score Top Affiliating Genes
1 metanephric adenoma 32.8 AMACR BRAF KRT7
2 childhood kidney cell carcinoma 32.0 MITF MSH2 PRCC
3 epithelial predominant wilms' tumor 32.0 AMACR KRT7 PRCC
4 mucinous tubular and spindle renal cell carcinoma 32.0 AMACR KRT7 PRCC
5 renal cell carcinoma, nonpapillary 31.1 AMACR KRT7 MET MITF MTOR PRCC
6 gastrointestinal stromal tumor 30.6 BRAF PTEN SDHB TP53
7 papillary carcinoma 30.5 BRAF ERBB2 KRT7 MET
8 clear cell renal cell carcinoma 30.4 KRT7 MET MTOR PTEN TP53 VHL
9 kidney cancer 30.3 MET MTOR TP53 VHL
10 tuberous sclerosis 30.3 MTOR PIK3CA RHEB VHL
11 clear cell papillary renal cell carcinoma 30.2 AMACR KRT7 MITF VHL
12 cystadenocarcinoma 30.2 ERBB2 HRAS KRT7 PIK3CA TP53
13 adenocarcinoma 30.1 BRAF ERBB2 FGFR3 HRAS PIK3CA PTEN
14 adenoid cystic carcinoma 30.1 ATM ERBB2 HRAS KRT7 PIK3CA PTEN
15 cholangiocarcinoma 30.1 BRAF ERBB2 KRT7 MET MTOR PIK3CA
16 transitional cell carcinoma 30.0 BRAF ERBB2 FGFR3 HRAS KRT7 MSH2
17 sarcoma 29.9 BRAF HRAS MTOR PIK3CA TP53
18 melanoma 29.9 BRAF MITF NRAS PTEN TP53
19 renal cell carcinoma, xp11-associated 11.5
20 hereditary leiomyomatosis and renal cell cancer 11.1
21 bejel 11.0
22 prostate adenoid cystic carcinoma 10.4 HRAS PIK3CA
23 paronychia 10.4 HRAS MTOR
24 benign struma ovarii 10.4 HRAS NRAS
25 hyperplastic polyposis syndrome 10.4 BRAF TP53
26 non-invasive bladder papillary urothelial neoplasm 10.4 FGFR3 TP53
27 vulvar intraepithelial neoplasia 10.4 KRT7 TP53
28 large intestine adenocarcinoma 10.4 KRT7 MTOR
29 ovarian germ cell teratoma 10.4 KRT7 NRAS
30 oncocytoma 10.4
31 breast ductal carcinoma 10.4 ERBB2 MET TP53
32 li-fraumeni syndrome 10.4 ATM PTEN TP53
33 prostate disease 10.4 AMACR PTEN TP53
34 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.4 PIK3CA PTEN TP53
35 dermatosis papulosa nigra 10.4 FGFR3 MTOR PIK3CA
36 uterine corpus serous adenocarcinoma 10.4 ERBB2 PIK3CA TP53
37 breast squamous cell carcinoma 10.4 ERBB2 PIK3CA TP53
38 uterine body mixed cancer 10.4 ERBB2 PIK3CA TP53
39 synchronous bilateral breast carcinoma 10.4 ATM PTEN TP53
40 ovarian melanoma 10.4 HRAS NRAS PTEN
41 malignant spiradenoma 10.4 KRT7 PIK3CA TP53
42 giant congenital nevus 10.4 HRAS NRAS
43 actinic cheilitis 10.4 FGFR3 MSH2 TP53
44 thyroid hurthle cell adenoma 10.4 PIK3CA PTEN
45 male reproductive system disease 10.4 AMACR PTEN TP53
46 meningeal melanomatosis 10.4 HRAS NRAS TP53
47 erdheim-chester disease 10.4 BRAF NRAS PIK3CA
48 uterine corpus cancer 10.4 ERBB2 PIK3CA TP53
49 spitz nevus 10.4 BRAF HRAS TP53
50 female reproductive endometrioid cancer 10.4 KRT7 PTEN TP53

Graphical network of the top 20 diseases related to Renal Cell Carcinoma, Papillary, 1:



Diseases related to Renal Cell Carcinoma, Papillary, 1

Symptoms & Phenotypes for Renal Cell Carcinoma, Papillary, 1

Clinical features from OMIM:

605074

Human phenotypes related to Renal Cell Carcinoma, Papillary, 1:

32
# Description HPO Frequency HPO Source Accession
1 papillary renal cell carcinoma 32 HP:0006766

UMLS symptoms related to Renal Cell Carcinoma, Papillary, 1:


flank pain

GenomeRNAi Phenotypes related to Renal Cell Carcinoma, Papillary, 1 according to GeneCards Suite gene sharing:

26 (show top 50) (show all 65)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.97 BRAF MTOR PIK3CA HRAS
2 Decreased viability GR00221-A-1 10.97 MTOR PIK3CA HRAS FGFR3 NRAS RHEB
3 Decreased viability GR00221-A-2 10.97 PIK3CA HRAS FGFR3 VHL
4 Decreased viability GR00221-A-3 10.97 ATM ERBB2 HRAS FGFR3 NRAS
5 Decreased viability GR00221-A-4 10.97 ATM BRAF ERBB2 MTOR PIK3CA
6 Decreased viability GR00301-A 10.97 BRAF VHL
7 Decreased viability GR00342-S-1 10.97 MTOR
8 Decreased viability GR00342-S-2 10.97 MTOR
9 Decreased viability GR00381-A-1 10.97 BRAF
10 Decreased viability GR00402-S-2 10.97 ATM BRAF ERBB2 MTOR PIK3CA HRAS
11 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.85 RHEB ATM MTOR
12 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.85 MET
13 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.85 RHEB ATM MTOR
14 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.85 FGFR3 ATM
15 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.85 NRAS
16 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.85 FGFR3 PRCC
17 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.85 ATM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.85 NRAS
19 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.85 ATM
20 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.85 MSH2 PTEN ATM
21 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.85 PTEN
22 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.85 PIK3CA
23 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.85 ATM
24 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.85 PTEN RHEB ATM MTOR PIK3CA PRCC
25 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.85 ERBB2 NRAS
26 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.85 PRCC
27 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.85 ERBB2 PRCC
28 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.85 MET
29 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.85 PIK3CA PRCC
30 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.85 ERBB2 PTEN
31 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.85 PRCC
32 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.85 MSH2 PRCC
33 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.85 PIK3CA
34 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.85 MET
35 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.85 MET
36 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.85 PIK3CA
37 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.85 PRCC
38 Increased shRNA abundance (Z-score > 2) GR00366-A-201 10.85 MET
39 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.85 ERBB2
40 Increased shRNA abundance (Z-score > 2) GR00366-A-208 10.85 NRAS
41 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.85 MSH2 PTEN ATM
42 Increased shRNA abundance (Z-score > 2) GR00366-A-215 10.85 ATM
43 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.85 NRAS
44 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.85 ERBB2
45 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.85 MET MSH2
46 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.85 ATM
47 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.85 PTEN RHEB MTOR PIK3CA
48 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.85 MSH2
49 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.85 PIK3CA
50 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.85 FGFR3

MGI Mouse Phenotypes related to Renal Cell Carcinoma, Papillary, 1:

46 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.54 AMACR ATM BRAF ERBB2 FGFR3 HRAS
2 cellular MP:0005384 10.52 ATM BRAF ERBB2 FGFR3 KRT7 MET
3 growth/size/body region MP:0005378 10.49 AMACR ATM BRAF ERBB2 FGFR3 HRAS
4 cardiovascular system MP:0005385 10.47 ATM BRAF ERBB2 HRAS MET MTOR
5 mortality/aging MP:0010768 10.46 AMACR ATM BRAF ERBB2 FGFR3 HRAS
6 behavior/neurological MP:0005386 10.44 ATM BRAF ERBB2 FGFR3 HRAS MET
7 embryo MP:0005380 10.41 ATM BRAF ERBB2 MET MITF MTOR
8 endocrine/exocrine gland MP:0005379 10.4 ATM BRAF ERBB2 HRAS MET MITF
9 immune system MP:0005387 10.4 ATM BRAF FGFR3 MET MITF MSH2
10 integument MP:0010771 10.36 ATM BRAF ERBB2 FGFR3 HRAS MITF
11 digestive/alimentary MP:0005381 10.35 BRAF ERBB2 FGFR3 HRAS MET MSH2
12 hematopoietic system MP:0005397 10.35 ATM BRAF FGFR3 MITF MSH2 MTOR
13 neoplasm MP:0002006 10.32 ATM BRAF ERBB2 FGFR3 HRAS MET
14 craniofacial MP:0005382 10.31 BRAF ERBB2 FGFR3 HRAS MET MITF
15 nervous system MP:0003631 10.3 ATM BRAF ERBB2 FGFR3 HRAS MET
16 normal MP:0002873 10.25 BRAF ERBB2 FGFR3 HRAS MET MITF
17 adipose tissue MP:0005375 10.23 AMACR ATM BRAF MTOR NFE2L2 PIK3CA
18 limbs/digits/tail MP:0005371 10.19 BRAF ERBB2 FGFR3 MET MITF NRAS
19 muscle MP:0005369 10.15 BRAF ERBB2 MET MTOR PIK3CA PTEN
20 liver/biliary system MP:0005370 10.13 AMACR BRAF MET NFE2L2 NRAS PTEN
21 no phenotypic analysis MP:0003012 10.09 FGFR3 HRAS MET MITF MTOR NRAS
22 renal/urinary system MP:0005367 10.06 BRAF FGFR3 HRAS KRT7 MET MTOR
23 reproductive system MP:0005389 9.91 ATM BRAF ERBB2 FGFR3 MITF PIK3CA
24 respiratory system MP:0005388 9.81 BRAF ERBB2 FGFR3 HRAS MET MTOR
25 pigmentation MP:0001186 9.77 BRAF MITF NRAS PTEN TP53
26 skeleton MP:0005390 9.73 BRAF ERBB2 FGFR3 HRAS MITF MTOR
27 vision/eye MP:0005391 9.28 BRAF FGFR3 MET MITF NRAS PIK3CA

Drugs & Therapeutics for Renal Cell Carcinoma, Papillary, 1

FDA approved drugs:

(show all 7)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Afinitor 18 49 EVEROLIMUS Novartis March 2009
2
Avastin 18 49 BEVACIZUMAB Genentech July 2009
3
Inlyta 18 49 AXITINIB Pfizer January 2012
4
Nexavar 18 49 SORAFENIB TOSYLATE Bayer/Onyx December 2005
5
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006
6
Torisel 18 49 TEMSIROLIMUS Wyeth May 2007
7
Votrient 18 49 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline April 2012/ October of 2009

Drugs for Renal Cell Carcinoma, Papillary, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
2
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
3
Bevacizumab Approved, Investigational Phase 2 216974-75-3
4
Nivolumab Approved Phase 2 946414-94-4
5
Fludarabine Approved Phase 1, Phase 2,Phase 2,Not Applicable 75607-67-9, 21679-14-1 30751
6
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2,Phase 2,Not Applicable 22916-47-8 4189
7
Vidarabine Approved, Investigational Phase 1, Phase 2,Phase 2,Not Applicable 24356-66-9 32326 21704
8
Mycophenolic acid Approved Phase 1, Phase 2,Phase 2,Not Applicable 24280-93-1 446541
9 Angiogenesis Modulating Agents Phase 2
10 Angiogenesis Inhibitors Phase 2
11 Protein Kinase Inhibitors Phase 2
12 tyrosine Phase 2
13 Mitogens Phase 2
14 Immunoglobulin G Phase 2
15 Antibodies Phase 2
16 Antibodies, Monoclonal Phase 2
17 Endothelial Growth Factors Phase 2
18 Immunoglobulins Phase 2
19 Immunologic Factors Phase 2,Phase 1,Not Applicable
20
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
21 Pharmaceutical Solutions Phase 2
22 Vidarabine Phosphate Phase 1, Phase 2,Phase 2,Not Applicable
23 Calcineurin Inhibitors Phase 1, Phase 2,Phase 2,Not Applicable
24 Antimetabolites, Antineoplastic Phase 1, Phase 2,Phase 2,Not Applicable
25 Cyclosporins Phase 1, Phase 2,Phase 2,Not Applicable
26 Antirheumatic Agents Phase 1, Phase 2,Phase 2,Not Applicable
27 Antibiotics, Antitubercular Phase 1, Phase 2,Phase 2,Not Applicable
28 Dermatologic Agents Phase 1, Phase 2,Phase 2,Not Applicable
29 Antimetabolites Phase 1, Phase 2,Phase 2,Not Applicable
30 Antiviral Agents Phase 1, Phase 2,Phase 2,Not Applicable
31 Antifungal Agents Phase 1, Phase 2,Phase 2,Not Applicable
32 Immunosuppressive Agents Phase 1, Phase 2,Phase 2,Not Applicable
33 Anti-Bacterial Agents Phase 1, Phase 2,Phase 2,Not Applicable
34 Anti-Infective Agents Phase 1, Phase 2,Phase 2,Not Applicable
35 Antitubercular Agents Phase 1, Phase 2,Phase 2,Not Applicable

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer Unknown status NCT00541008 Phase 2 sunitinib malate
2 CREATE: Cross-tumoral Phase 2 With Crizotinib Active, not recruiting NCT01524926 Phase 2 Crizotinib (PF-02341066)
3 Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer Suspended NCT02761057 Phase 2 Cabozantinib S-malate;Crizotinib;Savolitinib;Sunitinib Malate
4 Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer Completed NCT01727089 Phase 2
5 Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery Completed NCT01688973 Phase 2 Erlotinib Hydrochloride;Tivantinib
6 ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) Not yet recruiting NCT03685448 Phase 2 Cabozantinib
7 Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) Recruiting NCT03177239 Phase 2 Nivolumab;Ipilimumab
8 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Active, not recruiting NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
9 Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer Active, not recruiting NCT00027820 Phase 1, Phase 2 Fludarabine Phosphate;Cyclosporine;Mycophenolate Mofetil
10 Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer Active, not recruiting NCT00005799 Not Applicable fludarabine phosphate;cyclosporine;mycophenolate mofetil

Search NIH Clinical Center for Renal Cell Carcinoma, Papillary, 1

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: papillary renal cell carcinoma, sporadic

Genetic Tests for Renal Cell Carcinoma, Papillary, 1

Genetic tests related to Renal Cell Carcinoma, Papillary, 1:

# Genetic test Affiliating Genes
1 Renal Cell Carcinoma, Papillary, 1 29 MET PRCC
2 Papillary Renal Cell Carcinoma 29

Anatomical Context for Renal Cell Carcinoma, Papillary, 1

MalaCards organs/tissues related to Renal Cell Carcinoma, Papillary, 1:

41
Kidney, Thyroid, Bone, Lung, Ovary, Tonsil, Prostate

Publications for Renal Cell Carcinoma, Papillary, 1

Articles related to Renal Cell Carcinoma, Papillary, 1:

(show top 50) (show all 434)
# Title Authors Year
1
Expression of vitamin D receptor in clear cell papillary renal cell carcinoma. ( 29966830 )
2018
2
Clinical features and survival analysis of clear cell papillary renal cell carcinoma: A 10-year retrospective study from two institutions. ( 29963177 )
2018
3
A back-to-back tumor composed of papillary renal cell carcinoma and oncocytoma treated by laparoscopic partial nephrectomy: a case report. ( 29779490 )
2018
4
Takotsubo syndrome induced by malignant pheochromocytoma in a patient with type 2 papillary renal cell carcinoma - a case report. ( 29785166 )
2018
5
Distinct Genomic Copy Number Alterations Distinguish Mucinous Tubular and Spindle Cell Carcinoma of the Kidney From Papillary Renal Cell Carcinoma With Overlapping Histologic Features. ( 29462091 )
2018
6
Differentiation between papillary renal cell carcinoma and fat-poor angiomyolipoma: a preliminary study assessing detection of intratumoral hemorrhage with chemical shift MRI and T2*-weighted gradient echo. ( 29069911 )
2018
7
Three Primary Carcinomas on 18F-FDG PET/CT: Intrahepatic Cholangiocarcinoma, Papillary Renal Cell Carcinoma, and Clear Cell Renal Cell Carcinoma. ( 29561526 )
2018
8
Clear cell papillary renal cell carcinoma - An indolent subtype of renal tumor. ( 30037497 )
2018
9
Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases. ( 30072012 )
2018
10
Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma. ( 30448104 )
2018
11
The molecular characterization and therapeutic strategies of papillary renal cell carcinoma. ( 30474436 )
2018
12
Metastatic papillary renal cell carcinoma in the era of targeted therapy - a retrospective study from three European academic centres. ( 30507262 )
2018
13
Papillary Renal Cell Carcinoma (PRCC): An Update. ( 30507616 )
2018
14
Primary Extrarenal Type 2 Papillary Renal Cell Carcinoma: A Case Report. ( 30395891 )
2018
15
Cystic Appearance on Imaging Methods (Bosniak III-IV) in Histologically Confirmed Papillary Renal Cell Carcinoma is Mainly Characteristic of Papillary Renal Cell Carcinoma Type 1 and Might Predict a Relatively Indolent Behavior of Papillary Renal Cell Carcinoma. ( 30199877 )
2018
16
A TOP2A-derived cancer panel drives cancer progression in papillary renal cell carcinoma. ( 30214555 )
2018
17
Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan. ( 30224330 )
2018
18
Differentiation of Papillary Renal Cell Carcinoma Subtypes on MRI: Qualitative and Texture Analysis. ( 30240294 )
2018
19
Prevalence of Low-Attenuation Homogeneous Papillary Renal Cell Carcinoma Mimicking Renal Cysts on CT. ( 30240301 )
2018
20
Rare isolated synchronous splenic metastasis in a patient with type II papillary renal cell carcinoma. ( 30264005 )
2018
21
Answer to comment on manuscript "Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: results of an international multi-institutional study on 2189 patients". ( 30022407 )
2018
22
Diagnostic Accuracy of MRI for Detection of Papillary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. ( 30063398 )
2018
23
High proliferation rate and TNM-stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma. ( 30121370 )
2018
24
Type 1 Papillary Renal Cell Carcinoma Presenting as an Infected Benign Renal Cyst: an Uncommon Presentation. ( 29887714 )
2018
25
Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy. ( 29896907 )
2018
26
Can multiphase CT scan distinguish between papillary renal cell carcinoma type 1 and type 2? ( 29932401 )
2018
27
Machine learning models to predict the progression from early to late stages of papillary renal cell carcinoma. ( 29990647 )
2018
28
GCN2 is a potential prognostic biomarker for human papillary renal cell carcinoma. ( 29865032 )
2018
29
Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. ( 29685646 )
2018
30
Re: Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. ( 29704948 )
2018
31
Biphasic papillary renal cell carcinoma is a rare morphological variant with frequent multifocality: a study of 28 cases. ( 29119638 )
2018
32
Ipsilateral synchronous clear and papillary renal cell carcinoma: A case report and review of the literature. ( 29255679 )
2018
33
Fuhrman grading is inappropriate for papillary renal cell carcinoma. ( 29256019 )
2018
34
Papillary renal cell carcinoma with abscess formation: A report of three cases. ( 29343919 )
2018
35
The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. ( 29344091 )
2018
36
Recurrent papillary renal cell carcinoma with concomitant ipsilateral upper urinary tract urothelial carcinoma and metachronous urothelial carcinoma of the bladder. ( 29379740 )
2018
37
Type II papillary renal cell carcinoma with heterotrophic ossification: a case report. ( 29493352 )
2018
38
Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. ( 28592388 )
2018
39
Papillary Renal Cell Carcinoma: A Family Portrait. ( 28642022 )
2018
40
Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy. ( 28753789 )
2018
41
Validation of 34betaE12 immunoexpression in clear cell papillary renal cell carcinoma as a sensitive biomarker. ( 27923499 )
2017
42
Renal Cell Carcinoma with Angioleiomyoma-Like Stroma and Clear Cell Papillary Renal Cell Carcinoma: Exploring SDHB Protein Immunohistochemistry and the Relationship to Tuberous Sclerosis Complex. ( 29180251 )
2017
43
The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. ( 28695322 )
2017
44
Papillary renal cell carcinoma-derived chemerin, IL-8, and CXCL16 promote monocyte recruitment and differentiation into foam-cell macrophages. ( 28759013 )
2017
45
Prognostic value of vascular endothelial growth factor (VEGF), VEGF receptor 2, platelet-derived growth factor-I^ (PDGF-I^), and PDGF-I^ receptor expression in papillary renal cell carcinoma. ( 27989785 )
2017
46
GLUT1, MCT1/4 and CD147 overexpression supports the metabolic reprogramming in papillary renal cell carcinoma. ( 28028797 )
2017
47
Clear Cell Papillary Renal Cell Carcinoma: New Clinical and Imaging Characteristics. ( 28130179 )
2017
48
Imaging features of papillary renal cell carcinoma with cystic change-dominant appearance in the era of the 2016 WHO classification. ( 28534069 )
2017
49
hsa-mir-3199-2 and hsa-mir-1293 as Novel Prognostic Biomarkers of Papillary Renal Cell Carcinoma by COX Ratio Risk Regression Model Screening. ( 28338236 )
2017
50
Type 1 papillary renal cell carcinoma: differentiation from Type 2 papillary RCC on multiphasic MDCT. ( 28265706 )
2017

Variations for Renal Cell Carcinoma, Papillary, 1

UniProtKB/Swiss-Prot genetic disease variations for Renal Cell Carcinoma, Papillary, 1:

75 (show all 15)
# Symbol AA change Variation ID SNP ID
1 MET p.Met1131Thr VAR_006286 rs121913668
2 MET p.Val1188Leu VAR_006287 rs121913669
3 MET p.Leu1195Val VAR_006288 rs121913673
4 MET p.Val1220Ile VAR_006289 rs121913670
5 MET p.Asp1228Asn VAR_006290 rs121913671
6 MET p.Asp1228His VAR_006291
7 MET p.Tyr1230Cys VAR_006292 rs121913246
8 MET p.Tyr1230His VAR_006293 rs121913247
9 MET p.Met1250Thr VAR_006294 rs121913245
10 MET p.Val1092Ile VAR_032485 rs786202724
11 MET p.His1094Leu VAR_032486
12 MET p.His1094Arg VAR_032487 rs121913243
13 MET p.His1094Tyr VAR_032488 rs121913244
14 MET p.His1106Asp VAR_032489
15 MET p.Tyr1230Asp VAR_032491

ClinVar genetic disease variations for Renal Cell Carcinoma, Papillary, 1:

6 (show top 50) (show all 1426)
# Gene Variation Type Significance SNP ID Assembly Location
1 VHL NM_000551.3(VHL): c.548C> A (p.Ser183Ter) single nucleotide variant Pathogenic rs5030823 GRCh37 Chromosome 3, 10191555: 10191555
2 VHL NM_000551.3(VHL): c.548C> A (p.Ser183Ter) single nucleotide variant Pathogenic rs5030823 GRCh38 Chromosome 3, 10149871: 10149871
3 VHL NM_000551.3(VHL): c.481C> T (p.Arg161Ter) single nucleotide variant Pathogenic rs5030818 GRCh37 Chromosome 3, 10191488: 10191488
4 VHL NM_000551.3(VHL): c.481C> T (p.Arg161Ter) single nucleotide variant Pathogenic rs5030818 GRCh38 Chromosome 3, 10149804: 10149804
5 VHL NM_000551.3(VHL): c.499C> T (p.Arg167Trp) single nucleotide variant Pathogenic rs5030820 GRCh37 Chromosome 3, 10191506: 10191506
6 VHL NM_000551.3(VHL): c.499C> T (p.Arg167Trp) single nucleotide variant Pathogenic rs5030820 GRCh38 Chromosome 3, 10149822: 10149822
7 ATM ATM, IVS61DS, 2-BP INS, +2TA insertion Pathogenic
8 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
9 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
10 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
11 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
12 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
13 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
14 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
15 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
16 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
17 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
18 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
19 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
20 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
21 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
22 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
23 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
24 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
25 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
26 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
27 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
28 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
29 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
30 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
31 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
32 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
33 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
34 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
35 ERBB2 NM_001005862.2(ERBB2): c.2173_2174delTTinsCC (p.Leu725Pro) indel Pathogenic/Likely pathogenic rs121913469 GRCh37 Chromosome 17, 37880219: 37880220
36 ERBB2 NM_001005862.2(ERBB2): c.2173_2174delTTinsCC (p.Leu725Pro) indel Pathogenic/Likely pathogenic rs121913469 GRCh38 Chromosome 17, 39723966: 39723967
37 MET NM_001127500.2(MET): c.3446T> C (p.Met1149Thr) single nucleotide variant Pathogenic rs121913668 GRCh37 Chromosome 7, 116418881: 116418881
38 MET NM_001127500.2(MET): c.3446T> C (p.Met1149Thr) single nucleotide variant Pathogenic rs121913668 GRCh38 Chromosome 7, 116778827: 116778827
39 MET NM_001127500.2(MET): c.3616G> T (p.Val1206Leu) single nucleotide variant Pathogenic rs121913669 GRCh37 Chromosome 7, 116422081: 116422081
40 MET NM_001127500.2(MET): c.3616G> T (p.Val1206Leu) single nucleotide variant Pathogenic rs121913669 GRCh38 Chromosome 7, 116782027: 116782027
41 MET NM_001127500.2(MET): c.3712G> A (p.Val1238Ile) single nucleotide variant Pathogenic rs121913670 GRCh37 Chromosome 7, 116423383: 116423383
42 MET NM_001127500.2(MET): c.3712G> A (p.Val1238Ile) single nucleotide variant Pathogenic rs121913670 GRCh38 Chromosome 7, 116783329: 116783329
43 MET NM_001127500.2(MET): c.3736G> A (p.Asp1246Asn) single nucleotide variant Pathogenic/Likely pathogenic rs121913671 GRCh37 Chromosome 7, 116423407: 116423407
44 MET NM_001127500.2(MET): c.3736G> A (p.Asp1246Asn) single nucleotide variant Pathogenic/Likely pathogenic rs121913671 GRCh38 Chromosome 7, 116783353: 116783353
45 MET NM_001127500.2(MET): c.3743A> G (p.Tyr1248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913246 GRCh37 Chromosome 7, 116423414: 116423414
46 MET NM_001127500.2(MET): c.3743A> G (p.Tyr1248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913246 GRCh38 Chromosome 7, 116783360: 116783360
47 MET NM_001127500.2(MET): c.3637C> G (p.Leu1213Val) single nucleotide variant Pathogenic rs121913673 GRCh37 Chromosome 7, 116422102: 116422102
48 MET NM_001127500.2(MET): c.3637C> G (p.Leu1213Val) single nucleotide variant Pathogenic rs121913673 GRCh38 Chromosome 7, 116782048: 116782048
49 MET NM_001127500.2(MET): c.3335A> G (p.His1112Arg) single nucleotide variant Pathogenic rs121913243 GRCh37 Chromosome 7, 116417464: 116417464
50 MET NM_001127500.2(MET): c.3335A> G (p.His1112Arg) single nucleotide variant Pathogenic rs121913243 GRCh38 Chromosome 7, 116777410: 116777410

Cosmic variations for Renal Cell Carcinoma, Papillary, 1:

9 (show top 50) (show all 576)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM25676 VHL kidney,NS,carcinoma,renal cell c.485G>T p.C162F 3:10149808-10149808 66
2 COSM27269 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176L 3:124737785-124737785 66
3 COSM30474 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 5:14508136-14508136 66
4 COSM26594 RNF144A kidney,NS,carcinoma,renal cell c.410C>T p.A137V 2:7020581-7020581 66
5 COSM26987 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 1:241098672-241098672 66
6 COSM26614 RABGAP1 kidney,NS,carcinoma,renal cell c.1533T>A p.H511Q 9:123020414-123020414 66
7 COSM30530 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 66
8 COSM27618 KMT2A kidney,NS,carcinoma,renal cell c.5711C>T p.A1904V 11:118497991-118497991 66
9 COSM30502 ITPR3 kidney,NS,carcinoma,renal cell c.4574G>T p.C1525F 6:33682621-33682621 66
10 COSM28415 DOCK1 kidney,NS,carcinoma,renal cell c.1306G>T p.D436Y 10:127023241-127023241 66
11 COSM30531 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 4:83049959-83049959 66
12 COSM25654 CDC5L kidney,NS,carcinoma,renal cell c.1196G>A p.R399Q 6:44419552-44419552 66
13 COSM30471 ARHGAP20 kidney,NS,carcinoma,renal cell c.1355A>G p.D452G 11:110586276-110586276 66
14 COSM6941466 XIAP kidney,NS,carcinoma,renal cell carcinoma c.563G>C p.G188A 23:123886225-123886225 65
15 COSM14312 VHL kidney,NS,carcinoma,renal cell carcinoma c.353T>C p.L118P 3:10146526-10146526 65
16 COSM14380 VHL kidney,NS,carcinoma,renal cell carcinoma c.548C>A p.S183* 3:10149871-10149871 65
17 COSM18350 VHL kidney,NS,carcinoma,renal cell carcinoma c.256C>T p.P86S 3:10142103-10142103 65
18 COSM17957 VHL kidney,NS,carcinoma,renal cell carcinoma c.292T>G p.Y98D 3:10142139-10142139 65
19 COSM14382 VHL kidney,NS,carcinoma,renal cell carcinoma c.245G>C p.R82P 3:10142092-10142092 65
20 COSM14305 VHL kidney,NS,carcinoma,renal cell carcinoma c.266T>A p.L89H 3:10142113-10142113 65
21 COSM17875 VHL kidney,NS,carcinoma,renal cell carcinoma c.234T>G p.N78K 3:10142081-10142081 65
22 COSM17983 VHL kidney,NS,carcinoma,renal cell carcinoma c.500G>A p.R167Q 3:10149823-10149823 65
23 COSM18097 VHL kidney,NS,carcinoma,renal cell carcinoma c.482G>A p.R161Q 3:10149805-10149805 65
24 COSM14425 VHL kidney,NS,carcinoma,renal cell carcinoma c.341-2A>T p.? 3:10146512-10146512 65
25 COSM17872 VHL kidney,NS,carcinoma,renal cell carcinoma c.217C>T p.Q73* 3:10142064-10142064 65
26 COSM6957851 TSC2 kidney,NS,carcinoma,renal cell carcinoma c.541G>A p.V181M 16:2055461-2055461 65
27 COSM6942356 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.2287C>T p.Q763* 9:132902709-132902709 65
28 COSM6963117 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.1001C>A p.S334* 9:132911481-132911481 65
29 COSM29770 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.508+1G>T p.? 9:132923347-132923347 65
30 COSM10656 TP53 kidney,NS,carcinoma,renal cell carcinoma c.742C>T p.R248W 17:7674221-7674221 65
31 COSM45243 TP53 kidney,NS,carcinoma,renal cell carcinoma c.374C>G p.T125R 17:7675995-7675995 65
32 COSM10647 TP53 kidney,NS,carcinoma,renal cell carcinoma c.404G>T p.C135F 17:7675208-7675208 65
33 COSM44310 TP53 kidney,NS,carcinoma,renal cell carcinoma c.738G>A p.M246I 17:7674225-7674225 65
34 COSM6922197 TP53 kidney,NS,carcinoma,renal cell carcinoma c.97-2A>C p.? 17:7676274-7676274 65
35 COSM45135 TP53 kidney,NS,carcinoma,renal cell carcinoma c.673-1G>T p.? 17:7674291-7674291 65
36 COSM6929752 TBX3 kidney,NS,carcinoma,renal cell carcinoma c.510G>T p.W170C 12:114681026-114681026 65
37 COSM6979493 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.2096+1G>A p.? 23:124065947-124065947 65
38 COSM6975582 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.1348A>T p.R450* 23:124057909-124057909 65
39 COSM6023628 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.2860C>T p.R954C 23:124081464-124081464 65
40 COSM6963119 SPOP kidney,NS,carcinoma,renal cell carcinoma c.265T>G p.L89V 17:49619321-49619321 65
41 COSM989 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma c.1130G>A p.R377H 22:23834152-23834152 65
42 COSM6964939 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma c.987-2A>T p.? 22:23833570-23833570 65
43 COSM1266238 SMARCA4 kidney,NS,carcinoma,renal cell carcinoma c.3575G>A p.R1192H 19:11033318-11033318 65
44 COSM6947611 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.863C>A p.S288* 3:47122264-47122264 65
45 COSM6975580 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.4736C>G p.S1579* 3:47062211-47062211 65
46 COSM4118007 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.3266G>A p.R1089Q 3:47106061-47106061 65
47 COSM4794860 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.5922+1G>A p.? 3:47019759-47019759 65
48 COSM6925125 RBM10 kidney,NS,carcinoma,renal cell carcinoma c.179C>A p.S60* 23:47169476-47169476 65
49 COSM6922201 RBM10 kidney,NS,carcinoma,renal cell carcinoma c.299G>C p.G100A 23:47171125-47171125 65
50 COSM6947629 PTCH1 kidney,NS,carcinoma,renal cell carcinoma c.3616C>T p.R1206C 9:95449257-95449257 65

Expression for Renal Cell Carcinoma, Papillary, 1

Search GEO for disease gene expression data for Renal Cell Carcinoma, Papillary, 1.

Pathways for Renal Cell Carcinoma, Papillary, 1

Pathways related to Renal Cell Carcinoma, Papillary, 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 122)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.13 BRAF ERBB2 FGFR3 HRAS MET MTOR
2
Show member pathways
13.97 ATM BRAF ERBB2 FGFR3 HRAS MET
3
Show member pathways
13.65 BRAF ERBB2 FGFR3 HRAS MET MTOR
4
Show member pathways
13.6 BRAF ERBB2 FGFR3 HRAS KRT7 MET
5
Show member pathways
13.57 ERBB2 FGFR3 HRAS MET MTOR NRAS
6
Show member pathways
13.52 ERBB2 FGFR3 HRAS MET MTOR NRAS
7
Show member pathways
13.47 BRAF ERBB2 FGFR3 HRAS MET NRAS
8
Show member pathways
13.31 BRAF ERBB2 HRAS MTOR NRAS PTEN
9
Show member pathways
13.23 ERBB2 FGFR3 MET MTOR PIK3CA PTEN
10
Show member pathways
13.2 BRAF FGFR3 HRAS MET MTOR NRAS
11
Show member pathways
13.18 ATM HRAS MTOR NRAS PIK3CA PTEN
12
Show member pathways
13.14 FGFR3 HRAS MET MTOR NRAS RHEB
13
Show member pathways
13.11 ATM ERBB2 FGFR3 HRAS MET MTOR
14
Show member pathways
13.08 HRAS MTOR NRAS PIK3CA PTEN RHEB
15
Show member pathways
13.07 ATM MSH2 MTOR PTEN RHEB TP53
16
Show member pathways
13.05 BRAF ERBB2 HRAS MET MTOR NRAS
17
Show member pathways
13.03 BRAF ERBB2 HRAS MET NRAS PIK3CA
18
Show member pathways
13.02 BRAF HRAS MET NRAS PIK3CA TP53
19
Show member pathways
13.01 BRAF ERBB2 FGFR3 HRAS MTOR NRAS
20
Show member pathways
13 BRAF ERBB2 HRAS MSH2 MTOR NRAS
21
Show member pathways
12.9 BRAF HRAS MITF NRAS PIK3CA
22 12.9 BRAF ERBB2 FGFR3 HRAS MET NRAS
23
Show member pathways
12.89 ATM HRAS NRAS PIK3CA TP53
24 12.89 BRAF ERBB2 FGFR3 HRAS MET MITF
25
Show member pathways
12.88 ERBB2 FGFR3 HRAS MET MTOR NRAS
26
Show member pathways
12.88 BRAF ERBB2 HRAS MET MTOR NFE2L2
27
Show member pathways
12.86 BRAF HRAS MTOR PIK3CA PTEN
28
Show member pathways
12.86 BRAF FGFR3 HRAS MET NRAS PIK3CA
29
Show member pathways
12.86 BRAF ERBB2 HRAS MET MTOR NRAS
30
Show member pathways
12.82 ATM BRAF ERBB2 FGFR3 HRAS MET
31
Show member pathways
12.8 HRAS MTOR NRAS PIK3CA PTEN RHEB
32 12.73 BRAF FGFR3 HRAS NRAS PIK3CA
33
Show member pathways
12.72 ERBB2 HRAS MSH2 NRAS PIK3CA TP53
34
Show member pathways
12.7 BRAF ERBB2 HRAS MTOR NRAS PIK3CA
35
Show member pathways
12.69 BRAF FGFR3 HRAS NRAS PIK3CA
36
Show member pathways
12.64 HRAS MTOR PIK3CA PTEN RHEB
37
Show member pathways
12.63 ERBB2 HRAS MTOR NRAS PIK3CA PTEN
38 12.61 ATM ERBB2 FGFR3 HRAS MET MTOR
39
Show member pathways
12.57 HRAS MET MTOR PIK3CA PTEN RHEB
40
Show member pathways
12.56 HRAS MTOR PIK3CA RHEB TP53
41
Show member pathways
12.55 BRAF HRAS MITF MTOR NRAS
42 12.55 ATM HRAS NRAS PIK3CA TP53
43
Show member pathways
12.55 BRAF ERBB2 FGFR3 HRAS MET MTOR
44
Show member pathways
12.55 ATM ERBB2 FGFR3 HRAS MET MTOR
45
Show member pathways
12.55 BRAF ERBB2 HRAS MET MTOR NRAS
46
Show member pathways
12.53 HRAS MTOR NRAS PIK3CA RHEB
47
Show member pathways
12.51 BRAF HRAS NRAS PIK3CA PTEN
48
Show member pathways
12.5 BRAF HRAS MITF NRAS
49
Show member pathways
12.49 FGFR3 MTOR PIK3CA RHEB
50
Show member pathways
12.48 HRAS MET MTOR NRAS PIK3CA

GO Terms for Renal Cell Carcinoma, Papillary, 1

Cellular components related to Renal Cell Carcinoma, Papillary, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.85 ATM MITF MSH2 MTOR NFE2L2 PRCC
2 nucleus GO:0005634 9.8 ATM BRAF ERBB2 FGFR3 HRAS KRT7
3 cytoplasm GO:0005737 9.5 AMACR ATM BRAF ERBB2 FGFR3 HRAS

Biological processes related to Renal Cell Carcinoma, Papillary, 1 according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.98 ATM BRAF ERBB2 FGFR3 MET MTOR
2 cell proliferation GO:0008283 9.96 ERBB2 HRAS MET PTEN TP53
3 protein phosphorylation GO:0006468 9.95 ATM BRAF ERBB2 FGFR3 MET MTOR
4 peptidyl-tyrosine phosphorylation GO:0018108 9.88 BRAF ERBB2 FGFR3 MET
5 protein autophosphorylation GO:0046777 9.85 ATM ERBB2 FGFR3 MTOR
6 negative regulation of neuron apoptotic process GO:0043524 9.84 BRAF HRAS MSH2 PIK3CA
7 positive regulation of MAPK cascade GO:0043410 9.83 ERBB2 FGFR3 HRAS MET
8 cellular response to hypoxia GO:0071456 9.81 MTOR NFE2L2 PTEN TP53
9 phosphatidylinositol phosphorylation GO:0046854 9.8 ERBB2 FGFR3 MET PIK3CA
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.8 BRAF ERBB2 FGFR3 HRAS MET PTEN
11 Ras protein signal transduction GO:0007265 9.77 HRAS NRAS TP53
12 cellular response to drug GO:0035690 9.77 BRAF NFE2L2 TP53
13 positive regulation of protein kinase B signaling GO:0051897 9.77 ERBB2 FGFR3 MET MTOR PIK3CA
14 negative regulation of apoptotic process GO:0043066 9.76 BRAF ERBB2 FGFR3 MET MITF PTEN
15 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.74 ATM FGFR3 PIK3CA
16 MAPK cascade GO:0000165 9.73 BRAF ERBB2 FGFR3 HRAS MET NRAS
17 cell aging GO:0007569 9.65 HRAS MTOR TP53
18 cellular response to gamma radiation GO:0071480 9.63 ATM HRAS TP53
19 replicative senescence GO:0090399 9.62 ATM TP53
20 anoikis GO:0043276 9.62 MTOR PIK3CA
21 positive regulation of transcription by RNA polymerase III GO:0045945 9.61 ERBB2 MTOR
22 negative regulation of cell size GO:0045792 9.61 MTOR PTEN
23 regulation of axon regeneration GO:0048679 9.58 BRAF PTEN
24 cell cycle arrest GO:0007050 9.43 ATM HRAS MSH2 MTOR RHEB TP53
25 positive regulation of gene expression GO:0010628 9.28 ATM BRAF ERBB2 HRAS MITF MTOR

Molecular functions related to Renal Cell Carcinoma, Papillary, 1 according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.98 BRAF ERBB2 FGFR3 MET MTOR PTEN
2 ATP binding GO:0005524 9.97 ATM BRAF ERBB2 FGFR3 MET MSH2
3 protein binding GO:0005515 9.93 ATM BRAF ERBB2 FGFR3 HRAS KRT7
4 protein kinase binding GO:0019901 9.88 MSH2 MTOR PTEN RHEB TP53
5 kinase activity GO:0016301 9.8 ATM BRAF ERBB2 FGFR3 MET MTOR
6 protein tyrosine kinase activity GO:0004713 9.71 BRAF ERBB2 FGFR3 MET
7 protein phosphatase binding GO:0019903 9.67 ERBB2 MET TP53
8 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.63 ERBB2 FGFR3 MET
9 1-phosphatidylinositol-3-kinase activity GO:0016303 9.54 ATM FGFR3 PIK3CA
10 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.46 ERBB2 FGFR3 MET PIK3CA
11 nucleotide binding GO:0000166 9.28 ATM BRAF ERBB2 FGFR3 HRAS MET

Sources for Renal Cell Carcinoma, Papillary, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....